For example, the DESTINY-Breast04 trial, an open-label phase III study, showed a significant improvement in survival outcomes among advanced/metastatic HER2-low breast cancer patients treated with an antibody–drug conjugate (ADC), trastuzumab deruxtecan, compared with those treated with the chemotherapy regimen selected by physicians [5]. Here, ERBB2 is linked to breast carcinoma.